Edwards Lifesciences, Medtronic score CMS win over TAVR
Edwards Lifesciences (EW) and Medtronic (MDT) welcomed CMS's decision to expand Medicare coverage for TAVR to asymptomatic severe aortic stenosis patients, citing improved access and streamlined care. EW shares fell 2% to $84.31, MDT dropped 1% to $90.70. CMS's decision was based on EW's Early TAVR trial data, showing lower adverse outcomes for prompt TAVR. Analysts view the decision as positive for TAVR growth.
How this was made
The 30-second read
Why it matters
The decision is expected to increase TAVR utilization, but market pricing reflects short‑term uncertainty.
Market read
Regulatory news moves two large‑cap medtech stocks; sector may see longer‑term volume upside.
What to watch
Potential for local MACs to approve moderate AS treatment could limit immediate volume gains.
Background
CMS's national coverage decision removes evidence development requirements for symptomatic TAVR and adds asymptomatic patients, signaling policy shift.
Ticker impact
CMS expanded Medicare coverage for TAVR, causing EW shares to fall 2% during midday trading.
Short‑term downside pressure; potential rebound if procedure volumes rise.
First‑time disclosure of coverage change; large‑cap medtech with direct price reaction.
CMS coverage expansion for TAVR led MDT shares to drop 1% in midday trading.
Limited short‑term decline; watch for volume‑driven recovery.
First report of policy change; immediate market reaction.
Market effects
Broader medtech and cardiovascular device sector may see increased procedure volumes over time.
U.S. healthcare stocks could experience modest volatility as insurers adjust coverage policies.
International TAVR manufacturers may face competitive pressure if U.S. coverage expands.
Counterpoint
The coverage expansion could ultimately boost revenues, making the short‑term dip a buying opportunity.
Key entities
- CompanyEdwards Lifesciences
Manufacturer of TAVR devices, ticker EW.
- CompanyMedtronic
Manufacturer of TAVR devices, ticker MDT.
- RegulatorCMS
Centers for Medicare & Medicaid Services, issued the coverage decision.
